Welcome to our dedicated page for BioNexus Gene Lab SEC filings (Ticker: BGLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BioNexus Gene Lab's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BioNexus Gene Lab's regulatory disclosures and financial reporting.
BioNexus Gene Lab Corp reports initial insider holdings for director Yap Chee Keong. The disclosure lists a holding entry for common stock with 0.0000 shares owned directly as of the reported date, indicating no reportable direct equity position in the company’s common stock at that time.
BioNexus Gene Lab Corp reports initial insider holdings for director Low Jook Yuen. The filing shows beneficial ownership of 1,261 shares of common stock, held directly. This Form 3 establishes the director’s reported equity position as an insider of the company.
BioNexus Gene Lab Corp executive Chong Set Fui, the company's CFO, filed an initial statement of beneficial ownership. The filing reports 0 shares of BioNexus Gene Lab Corp common stock owned directly as of 2025-06-17, with no reported purchases, sales, or derivative positions.
BioNexus Gene Lab Corp. outlines continued progress toward commercializing the VitaGuard™ molecular residual disease (MRD) liquid‑biopsy platform in Southeast Asia after a working visit to Tongshu Gene facilities in Shanghai and Changzhou, where VitaGuard is in paid commercial use at numerous hospitals in China.
VitaGuard is a tumor‑naive, fixed‑panel next‑generation sequencing test for detecting circulating tumor DNA associated with MRD in solid tumors, designed to simplify repeat blood‑based monitoring. BioNexus holds exclusive rights for VitaGuard‑based products and services in ten Southeast Asian markets and owns approximately 15% of Fidelion Diagnostics, which holds VitaGuard intellectual‑property rights outside China.
Management has previously indicated an expected VitaGuard cost per test of under US$300, and the ten licensed markets together have a population of more than 680 million people. Following the visit, BioNexus and Fidelion are working on documentation transfer, local verification and validation, and regulatory and commercial preparations in Malaysia and Singapore, targeting initial deployment in selected regional medical hubs during 2026, subject to completion of this work and applicable approvals.
BioNexus Gene Lab Corp. highlighted its role in the 2026 China–Malaysia Economic Cooperation Outlook Forum, where CEO Sam Tan advocated moving Malaysia–China biotechnology ties beyond simple trade and toward co-development, clinical validation, and regional commercialization.
The company described a Malaysia-based ASEAN “execution hub” model using examples such as Fidelion Diagnostics and the VitaGuard™ MRD platform, linking China-origin biotechnology with international commercialization vehicles, clinical validation, and regulatory discipline. BioNexus emphasized precision diagnostics, liquid biopsy, minimal residual disease monitoring, and AI-assisted healthcare, and outlined collaboration pillars including accelerated validation of China-origin precision oncology tools, infrastructure for scalable labs, and AI-integrated healthcare that respects regional data sovereignty and privacy.
BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as Chief Commercial Officer of its affiliate Fidelion Diagnostics in connection with the Fidelion transaction. Fidelion is the international commercialization and intellectual property vehicle for the VitaGuard™ minimal residual disease liquid biopsy platform developed by Tongshu Gene.
Dr. Meyyappan will lead Fidelion’s global commercial strategy and partnerships to drive adoption of advanced oncology diagnostic technologies. BioNexus holds exclusive rights to commercialize VitaGuard™ across Southeast Asia through a licensing arrangement with Fidelion, supporting its strategy to expand access to precision oncology diagnostics in the region.
BioNexus Gene Lab Corp. announced it has completed a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., and appointed Matthew L. Barsing as Chairman alongside BioNexus CFO Angeline Chong as director on Chemrex’s streamlined two-member board.
The company has centralized financial supervision and strengthened capital expenditure review and reporting protocols at Chemrex to align more closely with parent-level governance standards. A previously approved staged capital allocation framework supports potential expansion initiatives, while Chemrex’s strategic options, including biotechnology and advanced manufacturing directions, remain under evaluation with no definitive commitments yet.